Laura Chico
Stock Analyst at Wedbush
(3.05)
# 1,341
Out of 4,964 analysts
212
Total ratings
43.33%
Success rate
0.51%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $34 → $42 | $24.21 | +73.48% | 8 | Aug 21, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $7.95 | +126.42% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $5.62 | +149.11% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $19.30 | +13.99% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $38.87 | +10.63% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $17.44 | +83.49% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $2.46 | +103.25% | 6 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $6.19 | +126.17% | 14 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $141 | $138.13 | +2.08% | 10 | Jul 31, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $35 → $34 | $30.08 | +13.03% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $13.87 | +22.57% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.52 | +111.27% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $3.90 | +284.62% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $133.33 | -2.50% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $136.36 | -11.26% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $23.70 | +13.92% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $4.12 | -2.91% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $15.60 | +92.31% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $22.02 | +18.07% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $14.44 | +197.89% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $23.52 | +82.86% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.26 | +138.10% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $6.51 | +330.11% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $28.22 | +2.76% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.24 | +867.74% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.42 | +104.68% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $18.56 | +126.29% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.59 | +1,765.36% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $5.30 | -5.66% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.66 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.97 | +68.35% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.60 | +851.92% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $10.47 | +6,776.79% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $65.39 | +328.20% | 1 | Apr 21, 2017 |
Dianthus Therapeutics
Aug 21, 2025
Maintains: Outperform
Price Target: $34 → $42
Current: $24.21
Upside: +73.48%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $7.95
Upside: +126.42%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.62
Upside: +149.11%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $19.30
Upside: +13.99%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $38.87
Upside: +10.63%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $17.44
Upside: +83.49%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.46
Upside: +103.25%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $6.19
Upside: +126.17%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $138.13
Upside: +2.08%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $30.08
Upside: +13.03%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $13.87
Upside: +22.57%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.52
Upside: +111.27%
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.90
Upside: +284.62%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $133.33
Upside: -2.50%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $136.36
Upside: -11.26%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $23.70
Upside: +13.92%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $4.12
Upside: -2.91%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $15.60
Upside: +92.31%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $22.02
Upside: +18.07%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.44
Upside: +197.89%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $23.52
Upside: +82.86%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.26
Upside: +138.10%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $6.51
Upside: +330.11%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $28.22
Upside: +2.76%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.24
Upside: +867.74%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.42
Upside: +104.68%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $18.56
Upside: +126.29%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.59
Upside: +1,765.36%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $5.30
Upside: -5.66%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.66
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.97
Upside: +68.35%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.60
Upside: +851.92%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $10.47
Upside: +6,776.79%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $65.39
Upside: +328.20%